An interventional study of P200TE in Glaucoma, sponsored by Optos, PLC. Completed at 2 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Optos, PLC · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 490 studies in Glaucoma with a site in United States — 75 open to participants now, 94 under way, 5 of them phase 3. Glaucoma · United States.
Among the 490 studies in Glaucoma with a site in United States, this one is the 222nd largest by enrollment of the 364 interventional ones that give a count, is one of 21 that started in 2024, is one of 163 with no phase, and was the 419th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →75 of the 490 studies in Glaucoma with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Tavo Biotherapeutics · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 30–90 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
490 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 88 · Phase 3 51 · Phase 4 66
First in 1976; this study’s year is marked. 21 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 79 across the 364 interventional studies, 100 across the 110 observational. Of the 358 that completed or were terminated, 138 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 490 have an industry lead sponsor. The 10 most frequent:
Optos, PLC is the lead sponsor of 18 studies on the registry; 3 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Optos, PLC has 8 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
34 of the studies in Glaucoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT07510087Marc Toeteberg-HarmsGlaucoma Related Quality of Life | 2026-11-30 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT06615661Iantrek, Inc.A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 490 studies in Glaucoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Images captured on the P200TE device on glaucoma patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
On pattern deviation (PD), there existed a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; or Glaucoma hemi-field test "outside normal limits;"
-Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities: Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage; and Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Various scans will be captured
Device: P200TE
SLO and OCT imaging
Also known as: OCT Device
Number of images collected
Time frame: 1 year
Ran from Feb 2024 to primary completion in Oct 2024, 8 months.
Of 58 industry-sponsored interventional studies with no phase under Glaucoma, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's 8 months is below that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Optos, PLC